Using infectious organisms to break
tumor immune tolerance may be an excellent therapeutic option for treating cancer in the future.
Not exact matches
Different classes of MHC molecules exist and are involved in immunity against pathogens and
tumor cells as well as the formation of
immune tolerance to self - antigens.
In the new study, scientists built upon previous discoveries that a safe, non-reproducing vaccine strain of T. gondii could cure mice of several types of solid
tumors, and identified which parasite proteins and which immunological pathways are required to break
immune tolerance.
Currently, the use of the bacterium Listeria monocytogenes to break the
immune tolerance of pancreatic
tumors is being explored in clinical trials and T. gondii may be similarly useful.
One promising strategy in the fight against cancer is to use the body's own
immune system to remove
tumor cells, but due to a phenomenon called
immune tolerance, the
immune system has a difficult time identifying which cells to attack.
When the
tumor - fighting T cells are kept in check by inhibitory regulatory T cells, scientists speak of «peripheral
immune tolerance.»
«New key regulator of acquisition of
immune tolerance to
tumor cells in cancer patients.»
Interestingly, this state of
immune tolerance is similar to what happens during pregnancy, and, more specifically, it's been found that the body's response to a
tumor is very similar to its response to embryonic tissues.
His lab has extensive experience evaluating and modulating T cell responses to
tumors and viruses, including introducing genes into T cells to impart specificity and modulate function, designing strategies to overcome
tolerance and enhance in vivo activity, and developing mouse models that more accurately model human
immune responses to candidate vaccines.
IDO1 has been implicated in
immune modulation through its ability to limit T cell function and engage mechanisms of
immune tolerance, and as such preventing
tumor rejection.